Samsung Epis Holdings Q1 2026: Profit Intact, Cash Bleeds ₩315.6B
A biosimilar holdco's debut full quarter: a 20% operating margin obscures a ₩315.6 billion operating cash deficit funded entirely by new short-term bank debt.
Source: Q1 2026 Quarterly Report (Period 2, Q1) — Filed May 15, 2026 with DART | Consolidated Financial Statements | Unit: ₩ billions
Samsung Epis Holdings was carved out of Samsung Biologics through a non-cash spin-off on November 1, 2025, making Q1 2026 the company's first complete operating quarter as an independent entity. The headline reads well: consolidated operating profit of ₩90.6 billion on ₩453.9 billion in revenue, implying an operating margin of approximately 20% — a credible result for a biosimilar platform whose eleven commercialized products ride the structural tailwind of originator patent expirations. The catch lies one level below the profit line. Inventories and receivables swelled by a combined ₩620 billion during the quarter, pulling operating cash flow to negative ₩315.6 billion despite the healthy profit. The entire shortfall was plugged by a ₩365.0 billion net increase in short-term borrowings, effectively doubling the company's outstanding bank debt in ninety days. Whether that working capital build is a one-time load-in or the beginning of a structural pattern is the central analytical question this filing raises.
Note on comparability: No prior-year income statement exists. Period 1 — the company's inaugural reporting period — ran from November 1 to December 31, 2025, a two-month stub that renders year-over-year profit comparisons structurally impossible. Operating trends are supplemented throughout this report with subsidiary Samsung Bioepis's standalone three-year revenue history.
